COVID-19 mRNA vaccine

Phase 2Vaccine

CanSino Biologics Inc.

COVID-19 mRNA vaccine is one of 42 biologic programs targeting COVID-19. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

InfluenzaActive, not recruiting

COVID-19Phase 1

Active, not recruiting

InfluenzaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Bnt162b2

BioNTech

Preclinical

29 2

COVID-19 Vaccine

Moderna

Preclinical

27 3

COVID-19 mRNA vaccine

CanSino Biologics Inc.

Phase 2

6 4

Achromycin V

WWyeth-Lederle Vaccines

Glucocorticoid

1 6

Nadroparin

GSK

Preclinical

1 7

Calcium

Eli Lilly

Preclinical

—8

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

4 9

Blood Taken

HHospices Civils de Lyon

Preclinical

1 10

MRNA COVID-19 Vaccine

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

COVID-19

NCT07215520

Clinical

Trials by Indication[1]

COVID-196 trials

Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older

Completed· CanSino Biologics Inc. logo

CanSino Biologics Inc.·Phase 1·NCT05373485·43 enrolled

Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults

Recruiting·CCastleVax Inc.·Phase 2·NCT07215520·200 enrolled

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above

Completed· GSK logo

GSK·Phase 3·NCT06374394·841 enrolled

Show 3 more trials

Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older

Completed· CanSino Biologics Inc. logo

CanSino Biologics Inc.·Phase 2·NCT05373472·150 enrolled

A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

Unknown status·CCNBG-Virogin Biotech (Shanghai) Ltd.·Phase 1·NCT06113744·164 enrolled

A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

Unknown status·CCNBG-Virogin Biotech (Shanghai) Ltd.·Phase 2·NCT06113731·980 enrolled

Vaccine1 trial

Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa

Completed·VVaccine Company, Inc.·Phase 1·NCT05938075·130 enrolled

Clinical Trial1 trial

A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above

Completed·SStemirna Therapeutics·Phase 1/2·NCT05144139·480 enrolled

Influenza1 trial

Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

Completed· Sanofi logo

Sanofi·Phase 2·NCT04969276·306 enrolled

Immunogenicity1 trial

A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster

Withdrawn·WWuhan Rhegen Biotechnology Co., Ltd.·Phase 1·NCT05609045

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for COVID-19 mRNA vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — COVID-19 mRNA vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for COVID-19 mRNA vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CanSino Biologics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 2[1]
Company: CanSino Biologics Inc.

COVID-19 mRNA vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

COVID-196 trials

Vaccine1 trial

Clinical Trial1 trial

Influenza1 trial

Immunogenicity1 trial

References

Drug Info

Quick Facts

Related News